Peter Andersen
Chairman at IMMUNOVIA AB
Profile
Peter Høngaard Andersen was the founder of ACADIA Pharmaceuticals A, where he held the title of Vice President from 1997 to 1999.
He is also the founder of Zealand Pharma A, Glycom A, EpiTherapeutics ApS, Prexton Therapeutics SA, and InnovationsFonden.
Dr. Andersen's current job(s) include being the Chairman of the European Federation of Pharmaceutical Industries & Assns since 2014, Chairman of Immunovia AB since 2023, Chairman of Biotech Research & Innovation Centre, Chairman of Edvince AB, Director of Ossianix, Inc., Operating Partner of Forbion Capital Partners Management Holding BV since 2022, and a Member of Collegium Internationale Neuro-Psychopharmacologicum and Scandinavian Society for Psychopharmacology.
His former job(s) include being the Chairman of Lundbeck Research USA, Inc., Vice-Chairman of Scandion Oncology A in 2019, Director-Supervisory Board of to-BBB Holding BV, Director & Executive Vice President-Research of Lundbeck Pharma A from 2011 to 2014, Director of Serendex Pharmaceuticals A, Director of Imara, Inc., Director of Monsenso A, Project Manager-Metabolic Disease at Novo Nordisk A from 1984 to 1987, SVP-External Scientific Relations & Patents at H.
Lundbeck A, and Member-Supervisory Board of to-BBB technologies BV.
He was also a Venture Partner at Ysios Capital Partners SGEIC SA from 2020 to 2023.
Dr. Andersen obtained his graduate and doctorate degrees from the University of Copenhagen.
Dr. Andersen is also the founder of Zealand Pharma A, Glycom A, EpiTherapeutics ApS, Prexton Therapeutics SA, and InnovationsFonden.
Peter Andersen active positions
Companies | Position | Start |
---|---|---|
IMMUNOVIA AB | Chairman | 2023-05-25 |
Prexton Therapeutics SA
Prexton Therapeutics SA Pharmaceuticals: MajorHealth Technology Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland. | Founder | - |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Private Equity Investor | 2022-07-19 |
Biotech Research & Innovation Centre | Chairman | - |
Scandinavian Society for Psychopharmacology | Corporate Officer/Principal | 2010-06-03 |
Ossianix, Inc.
Ossianix, Inc. Pharmaceuticals: GenericHealth Technology Ossianix, Inc. develops single domain antibodies. It develops biotherapeutic products using the versatile single domain VNAR antibody from the shark and also developed highly innovative approaches to target specific cells and tissues such as the brain via the blood brain barrier and peripheral nerve via the neuromuscular junction. The company was founded by Frank S. Walshin, J. Lynn Rutkowski and Corey S. Goodman in 2011 and is headquartered in Philadelphia, PA. | Director/Board Member | - |
Collegium Internationale Neuro-Psychopharmacologicum | Corporate Officer/Principal | 2010-06-03 |
European Federation of Pharmaceutical Industries & Assns
European Federation of Pharmaceutical Industries & Assns Miscellaneous Commercial ServicesCommercial Services The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium. | Chief Tech/Sci/R&D Officer | - |
Edvince AB
Edvince AB BiotechnologyHealth Technology Edvince AB engages in clinical research and development services. It operates as a biotech company that focuses on a new form of emergency treatment for stroke. The company was founded by Lars Ingvar Herbert Edvinsson in 2003 and is headquartered in Lund, Sweden. | Chairman | - |
Former positions of Peter Andersen
Companies | Position | End |
---|---|---|
░░░░░ ░░░░░░░ ░░░░░░░░ ░░░░░ ░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░░░░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░ | ░░░░░░░░░░ |
░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░ | - |
Training of Peter Andersen
University of Copenhagen | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 6 |
---|---|
NOVO NORDISK A/S | Health Technology |
H. LUNDBECK A/S | Health Technology |
ZEALAND PHARMA A/S | Health Technology |
IMMUNOVIA AB | Health Technology |
MONSENSO A/S | Technology Services |
SCANDION ONCOLOGY A/S | Health Technology |
Private companies | 19 |
---|---|
Lundbeck Research USA, Inc.
Lundbeck Research USA, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Research USA, Inc. develops pharmaceutical products and information to the medical community. The firm engages in the drug discovery aimed at treating central nervous system diseases by designing small molecule therapeutics. The company was founded in 1990 and is headquartered in Paramus, NJ. | Health Technology |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Finance |
European Federation of Pharmaceutical Industries & Assns
European Federation of Pharmaceutical Industries & Assns Miscellaneous Commercial ServicesCommercial Services The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium. | Commercial Services |
to-BBB Holding BV
to-BBB Holding BV Pharmaceuticals: GenericHealth Technology to-BBB Holding BV operated as a holding company with interest in providing central nervous system drug technology to the pharmaceutical and biotechnology industries. The firm developed medicines for the treatment of brain diseases. The company was headquartered in The Hague, the Netherlands. | Health Technology |
to-BBB technologies BV
to-BBB technologies BV Pharmaceuticals: MajorHealth Technology BBB Therapeutics BV develops medicines for brain disease treatment. The firm uses its platform technology to enhance the delivery of established and marketed drugs over the blood brain-barrier. It offers its patented central nervous system (CNS) drug targeting technology to their partners in pharmaceutical and biotechnology industry. The firm's products include 2B3-101 and 2B3-201. The company was founded by Pieter Jaap Gaillard, Bert de Boer, and Alfred N. Nijkerk in 2003 and is headquartered in Leiden, the Netherlands. | Health Technology |
Glycom A/S
Glycom A/S BiotechnologyHealth Technology Glycom A/S engages in the development, synthesis, and commercialization of human milk oligosaccharides. It develops chemical and enzymatic technologies for synthesis of human milk oligosaccharide powders. The company was founded by Gyuala Dekany, Mark von Itzstein, Joachim Erich Thiem, Arnold Stutz, and Inge Lundt on March 22, 2005 and is headquartered in Horsholm, Denmark. | Health Technology |
Collegium Internationale Neuro-Psychopharmacologicum | |
Ysios Capital Partners SGEIC SA
Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Finance |
ACADIA Pharmaceuticals A/S
ACADIA Pharmaceuticals A/S Miscellaneous Commercial ServicesCommercial Services Part of ACADIA Pharmaceuticals, Inc., ACADIA Pharmaceuticals A/S utilizes technology to fuel drug discovery and clinical development. The private company is based in Glostrup, Denmark. The Danish company was founded by Peter Høngaard Andersen. | Commercial Services |
EpiTherapeutics ApS
EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Health Technology |
Lundbeck Pharma A/S
Lundbeck Pharma A/S Medical DistributorsDistribution Services Lundbeck Pharma A/S markets and sells medicines within Central Nervous System. It specializes in various illnesses and conditions such as depression, Schizophrenia, anxiety, alcohol dependence, and Parkinson's and Alzheimer's diseases. The company was founded on January 1, 1988 and is headquartered in Valby, Denmark. | Distribution Services |
Scandinavian Society for Psychopharmacology | |
Serendex Pharmaceuticals A/S
Serendex Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Serendex Pharmaceuticals A/S engages in the research and development of pharmaceuticals for respiratory conditions. It develops drugs to treat respiratory conditions such as Pulmonary Alveolar Proteinosis, Bronchiectasis, Cystic Fibrosis related lung infections and Diffuse Alveolar Hemorrhage. The company was founded by Lars Heslet on October 31, 2008 and is headquartered in Horsholm, Denmark. | Health Technology |
Ossianix, Inc.
Ossianix, Inc. Pharmaceuticals: GenericHealth Technology Ossianix, Inc. develops single domain antibodies. It develops biotherapeutic products using the versatile single domain VNAR antibody from the shark and also developed highly innovative approaches to target specific cells and tissues such as the brain via the blood brain barrier and peripheral nerve via the neuromuscular junction. The company was founded by Frank S. Walshin, J. Lynn Rutkowski and Corey S. Goodman in 2011 and is headquartered in Philadelphia, PA. | Health Technology |
Prexton Therapeutics SA
Prexton Therapeutics SA Pharmaceuticals: MajorHealth Technology Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland. | Health Technology |
Biotech Research & Innovation Centre | |
InnovationsFonden
InnovationsFonden Investment ManagersFinance InnovationsFonden provides investment services. It invests in entrepreneurs, researchers, and businesses. The company was founded on January 4, 2005 and is headquartered in Copenhagen, Denmark. | Finance |
Edvince AB
Edvince AB BiotechnologyHealth Technology Edvince AB engages in clinical research and development services. It operates as a biotech company that focuses on a new form of emergency treatment for stroke. The company was founded by Lars Ingvar Herbert Edvinsson in 2003 and is headquartered in Lund, Sweden. | Health Technology |
Imara, Inc.
Imara, Inc. Pharmaceuticals: MajorHealth Technology Imara, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. The company was founded by James Gregg McArthur in 2016 and is headquartered in Brookline, MA. | Health Technology |
- Stock Market
- Insiders
- Peter Andersen